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Abstract
AIM: To evaluate the effects of surgical weight loss 
(Roux-en-Y gastric bypass with a modified Fobi-Capella 
technique) on non alcoholic fatty liver disease in obese 
patients.
METHODS: A group of 26 morbidly obese patients 
aged 45 ± 2 years and with a body mass index > 40 
kg/m2 who underwent open surgical weight loss opera-
tions had paired liver biopsies, the first at surgery and 
the second after 16 ± 3 mo of weight loss. Biopsies 
were evaluated and compared in a blinded fashion. The 
presence of metabolic syndrome, anthropometric and 
biochemical variables were also assessed at baseline 
and at the time of the second biopsy. 
RESULTS: Percentage of excess weight loss was 
72.1% ± 6.6%. There was a reduction in prevalence of 
metabolic syndrome from 57.7% (15 patients) to 7.7% 
(2 patients) (P  < 0.001). Any significance difference 
was observed in aspartate aminotransferase or alanine 
aminotransferase between pre and postsurgery. There 
were improvements in steatosis (P  < 0.001), lobular 
(P  < 0.001) and portal (P  < 0.05) inflammation and 
fibrosis (P  < 0.001) at the second biopsy. There were 
25 (96.1%) patients with non alcoholic steatohepatitis 
(NASH) in their index biopsy and only four (15.3%) 
of the repeat biopsies fulfilled the criteria for NASH. 
The persistence of fibrosis (F > 1) was present in five 
patients at second biopsy. Steatosis and fibrosis at sur-
gery were predictors of significant fibrosis postsurgery.
CONCLUSION: Restrictive mildly malabsorptive sur-
gery provides significant weight loss, resolution of 
metabolic syndrome and associated abnormal liver his-
tological features in most obese patients.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
The term non alcoholic fatty liver disease (NAFLD) 
includes a spectrum of  fatty liver diseases ranging from 
simple steatosis to steatohepatitis [non alcoholic steato-
hepatitis (NASH)] and cirrhosis[1]. The more progres-
sive forms of  NAFLD have been related to metabolic 
syndrome and obesity[2]. The epidemic of  obesity has 
increased the prevalence of  NAFLD and it is already 
the most common liver disorder in developed coun-
tries. Morbid obese patients have a high proportion of  
NAFLD. Most patients undergoing bariatric surgery have 
varying degrees of  steatosis: as many as 36% have NASH 
and up to 4% have unsuspected cirrhosis. Only a small 
percentage of  patients undergoing bariatric surgery have 
normal hepatic histology[3].
The optimal treatment of  NASH has yet to be elu-
cidated. In general, efforts have been developed to cor-
rect or improve insulin resistance and, in obese patients, 
weight loss has been prescribed. The effects of  weight 
loss on NAFLD lesions have been studied and the re-
ported effects of  this therapy have been variable. Diet 
induced weight loss improved steatosis but did not always 
demonstrate an effect on histological parameters since in 
most studies repeated liver biopsy was not performed[3-8].
Also the effect of  bariatric surgery could be con-
founding. Initially, it was described that rapid weight loss 
can exacerbate steatohepatitis in morbidly obese patients, 
especially after bariatric surgery[9]. This effect was more 
marked when malabsorptive procedures, like jejunoileal 
bypass or biliopancreatic diversion, were used. More re-
cently, restrictive procedures, such as laparoscopic adjust-
able gastric banding, have demonstrated significant im-
provement in histopathological scoring[10-12], but in some 
studies the improvement in steatosis was accompanied by 
a progression of  lobular inflammation[13].
We have less information about the effects on patients 
when mixed procedures were used[14]. The most frequently 
performed is Roux-en-Y gastric bypass, largely restrictive 
and mildly malabsorptive. In this procedure, the restric-
tion is induced by a small neogastric pouch and a tight 
stoma and malabsorption by Roux-en-Y configuration 
of  the small intestine[15]. The purpose of  this study was 
to determine whether significant weight loss achieved 
through a standard mixed procedure - Roux-en-Y gastric 
bypass[16,17] - of  bariatric surgery resulted in improvements 
in liver histopathology.
MATERIALS AND METHODS
Since May 2004, a prospective protocol has been fol-
lowed for patients with morbid obesity that had a Roux-
en-Y gastric bypass. Up to September 2005, twenty-six 
obese patients with a body mass index of  more than 40 
kg/m2 who had significant medical, physical or psychoso-
cial disabilities were considered for entry into the study. 
All patients underwent extensive preoperative assessment 
that included alcohol consumption, anthropometric mea-
surements and laboratory tests. Laboratory tests included 
liver function tests, lipid profile, fasting plasma glucose, 
fasting insulin and hepatitis B and C serological analysis. 
Diagnosis of  type 2 diabetes was based on the American 
Diabetes Association criteria[18]. Insulin sensitivity was es-
timated using the homeostatic model assessment method 
(HOMA)[19]. A diagnosis of  metabolic syndrome was 
based on Adult Treatment Panel Ⅲ criteria[20]. At the time 
of  the second biopsy, the clinical assessment and anthro-
pometric and biochemical measures were repeated. Per-
centage of  excess weight loss was calculated by dividing 
the weight change between paired biopsies by the excess 
weight before surgery, multiplied by 100. 
Any patient with a history of  alcoholism, consuming 
more than 200 g of  alcohol per week, with evidence of  
hepatitis B or C or with a history of  another specific liver 
disease, was included in the study. 
An open Roux-en-Y gastric bypass with a modified Fo-
bi-Capella technique (ring 7 cm; alimentary limb 225 cm; 
biliopancreatic limb 60 cm) was performed in all patients.
An index biopsy was taken at the time of  surgery with 
a Hepafix needle. In all patients, a follow up biopsy was 
obtained as a percutaneous biopsy using a Hepafix needle. 
All biopsies were at least 2 cm in length and contained at 
least eight portal tracts. Informed written consent was also 
obtained from all patients at the time of  the index biopsy 
as part of  an approved prospective study of  bariatric sur-
gery. Informed written consent also was obtained from all 
subjects before the second biopsy and the study was con-
ducted according to the ethical guidelines of  the Helsinki 
Declaration.
All liver biopsy specimens were stained with hema-
toxylin eosin, picrosiriums for fibrosis and periodic acid 
Schiff  (PAS) with diastase to help clarify the degree of  
inflammation. 
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A single hepatopathologist (HA), blinded to the 
patient, clinical and laboratory data and to whether the 
biopsy was the pre or post operative biopsy, examined all 
tissue sections at the same time and assessed liver histol-
ogy using a systemic approach of  necroinflammatory 
grading and fibrosis staging as described by Brunt et al[21] 
and modified by Kleine et al[22]. Individual histological 
features were observed and scored separately (Table 1): 
Steatosis: 0: None; 1: Up to 33%; 2: 33%-66%; 3: > 66%. 
Hepatocyte ballooning: 0: None; 1: Occasional, Zone 3; 
2: “Obvious” Zone 3; 3: Marked, predominantly Zone 3. 
Mallory bodies: 0: No Mallory bodies; 1: Fewer than two 
in 10 to 20 × fields; 2: More than two in 10 to 20 × fields. 
Glycogenated nuclei: 0: Absent; 1: Occasional; 2: Several. 
Lobular inflammation (inflammatory foci per 20 × with 
a 20 × ocular): 0: None; 1: 1 to 2/20; 2: Up to 4/20; 3: 
More than 4/20. Portal inflammation: 0: None; 1: Mild; 2: 
Moderate; 3: Severe. Fibrosis score: Stage 0: No fibrosis; 
Stage 1: Zone 3 perisinusoidal/pericellular fibrosis; focally 
or extensively present; Stage 2: Zone 3 perisinusoidal/
pericellular fibrosis with focal or extensive periportal fi-
brosis; Stage 3: Zone 3 perisinusoidal/pericellular fibrosis 
and portal fibrosis with a focal or extensive bridging fibro-
sis; Stage 4: Cirrhosis.
 Finally, all were graded and staged for NASH accord-
ing to the system proposed at the American Association 
for the Study of  Liver Diseases single topic conference in 
September 2002[23].
Also, for each patient, the following variables were 
assessed at baseline and at the moment of  second liver 
biopsy: age, waist circumference, weight, percentage ex-
cess weight loss, body mass index (BMI), alanine amino-
transferase (ALT) level, aspartate aminotransferase (AST) 
level, gamma-glutamyl transferase level, bilirubin level, 
serum triglyceride level, cholesterolemia, serum high den-
sity lipoprotein cholesterol, serum low density lipopro-
tein cholesterol, blood glucose level, fasting insulin level, 
HOMA, steatosis amount, portal and lobular inflamma-
tion, fibrosis score and grade of  NASH. The relationship 
between persistence of  liver fibrosis after surgery (F > 
1) and various risk factors was studied using a univariate 
analysis. In the univariate analysis, 2 groups were com-
pared according to the presence or absence of  significant 
fibrosis (F > 1) in the liver biopsy.
Statistical analysis of  clinical and laboratory data was 
assessed using a paired samples t test. For histological 
comparisons pre-surgery and post-surgery, paired t tests 
were confirmed with Wilcoxon signed rank tests.
RESULTS
There were 26 patients (7 male and 19 female) with 
paired biopsies. Patient characteristics are shown in Table 
2. There were no patients with cirrhosis and no complica-
tions from the gastric bypass or deaths during this study. 
The second biopsy was obtained 16.3 ± 3 mo (range: 
12-22 mo) after bariatric surgery and no complications 
(bleeding, biloma, etc.) were observed during this postop-
erative percutaneous liver biopsy. 
The percentage of  excess weight loss was 72.1% ± 
6.6% and the average rate of  weight loss was 0.69 ± 0.22 
kg/wk. Other clinical demographic and weight loss data 
are shown in Table 1. Weight loss was accompanied by 
significant favorable changes in anthropometric mea-
sures, significant decreases in blood pressure and major 
improvements in biochemical markers of  metabolic 
syndrome, plasma glucose, insulin levels, insulin sensi-
tivity and cholesterol levels (Table 1). Fifteen of  the 26 
patients (57.7%) fulfilled criteria for metabolic syndrome 
and only 2 (7.7%) fulfilled these criteria at the follow-up. 
Preoperatively, 7 (27%) patients had abnormal alanine 
aminotransferase or aspartate aminotransferase (> 0.58 
µkat/L); postoperatively only 3 had abnormal alanine 
aminotransferase or an aspartate aminotransferse levels 
(> 0.58 µkat/L). There were no significant differences in 
aminotransferase levels with weight loss.
Histopathological results
Significant histopathological improvement was seen in 
steatosis (P < 0.001), ballooning degeneration (P < 0.001), 
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Table 1  Criteria used for histological scoring[21]
Steatosis:
   0 : None
   1: up to 33%
   2: 33%-66%
   3: > 66%
Hepatocyte ballooning
   0: None
   1: Occasional, Zone 3
   2: “Obvious” Zone 3
   3: Marked, predominantly Zone 3
Mallory bodies
   0: No Mallory bodies
   1: Fewer than two in 10 to 20 × fields
   2: More than two in 10 to 20 × fields
Glycogenated nuclei
   0: Absent
   1: Occasional
   2: Several
Lobular inflammation (inflammatory foci per 20 × with a 20 × ocular)
   0: None
   1: 1 to 2/20
   2: Up to 4/20
   3: More than 4/20
Portal inflammation
   0: None
   1: Mild
   2: Moderate
   3: Severe
Fibrosis score:
   Stage 0: No fibrosis
   Stage 1: Zone 3 perisinusoidal/pericellular fibrosis; focally or 
   extensively present
   Stage 2: Zone 3 perisinusoidal/pericellular fibrosis with focal or 
   extensive periportal fibrosis
   Stage 3: Zone 3 perisinusoidal/pericellular fibrosis and portal fibrosis 
   with a focal or extensive bridging fibrosis
   Stage 4: Cirrhosis
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Mallory bodies (P = 0.005), glycogen nuclei (P = 0.001), 
lobular inflammation (P < 0.001), portal inflammation (P 
= 0.005) and fibrosis (P < 0.001) (Figure 1 and Table 3).
We classified subjects as having NASH if  their biopsy 
scored at least 1 for both grade and stage. There were 
25 patients (96%) with NASH in their index biopsy. By 
contrast, only 4 (15.3%) of  the follow up biopsies dem-
onstrated NASH (P < 0.001). Table 4 shows scoring for 
the grade and stage of  NASH in liver biopsies performed 
at surgery and during follow up. None of  the second 
biopsies revealed progression of  grade or stage of  liver 
disease.
The changes in steatosis are perhaps one of  the more 
significant features in this analysis. Steatosis score im-
proved overall by two or more grades in 12 patients and 
by one grade in 14 patients. Although portal inflamma-
tion improved significantly, it disappeared in only seven 
patients; after surgery, some degree of  portal inflamma-
tion persisted in 19 patients. 
Although the change in fibrosis was significant, it 
was not constant. Fibrosis score improved overall by two 
stages in 1 patient and by one stage in 10 patients. In 15 
patients, fibrosis remained stable and we did not observe 
any patient with worsening of  liver fibrosis (Figure 2). 
Eight patients had significant fibrosis (F > 1) before 
surgery. At the second liver biopsy, five patients still had 
significant fibrosis (Figure 3). In univariate analysis, pa-
tients with significant liver fibrosis after surgery had a sig-
nificantly higher steatosis score, higher fibrosis score and 
lower AST level at the time of  surgery than patients with-
out (Table 5). After bariatric surgery, one of  two patients 
with metabolic syndrome and none of  the 6 patients with 
diabetes had a fibrosis score greater than 1 in the liver 
biopsy. There was no difference in the interval between 
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Figure 1  Marked improvement of liver fibrosis (left panel; picrosirius stain, ×10) and liver steatosis (right panel; osmium stain ×20) before (A) and after (B) 
bariatric surgery. 
Liver fibrosis                                Liver steatosis Liver fibrosis                                Liver steatosis
Table 2  Changes in anthropometric measurements and 
biochemistry between the patients’ first and second liver 
biopsy
Pre bariatric 
surgery
Post bariatric 
surgery
P  value
Weight (kg)     130.8 ± 20.1   82.3 ± 13.7 < 0.001
BMI (kg/m2)     49.3 ± 4.8 30.9 ± 4.3 < 0.001
% excess weight loss 72.1 ± 6.6
Waist (cm)     137.1 ± 12.6   97.3 ± 11.0 < 0.001
Diabetic (%)   12 (46.1)         6 (23)   0.14
Hypertensive (%)   17 (65.4)         7 (26.9)     0.012
Metabolic syndrome   15 (57.7)         2 (7.7) < 0.001
Cholesterol (mmol/L)     5.44 ± 1.00   4.29 ± 0.85 < 0.001
HDL-C (mmol/L)     1.24 ± 0.21   1.40 ± 0.19     0.005
LDL-C (mmol/L)     3.47 ± 0.76   2.46 ± 0.75 < 0.001
Triglycerides (mmol/L)     1.60 ± 0.63   0.93 ± 0.29 < 0.001
AST (µkat/L)     0.35 ± 0.09   0.36 ± 0.17     0.862
ALT (µkat/L)     0.49 ± 0.20   0.37 ± 0.31     0.143
GGT (U/L)     40.2 ± 17.4   19.2 ± 12.8 < 0.001
Fasting glucose (mmol/L)   6.46 ± 2.3   4.96 ± 0.55     0.001
Insulin (pmol/L) 235.2 ± 7.2 56.1 ± 7.2     0.006
Insulin resistance (HOMA)     9.99 ± 13.3   1.8 ± 1.4     0.006
Table 3  Histological scores for the 26-paired biopsies
Scores P  value
Feature   0   1   2 3 4
Steatosis < 0.001
  Pre   0 13   8 5 -
  Post 24   2   0 0 -
Ballooning degeneration < 0.001
  Pre 10   8   7 1 -
  Post 25   1   0 0 -
Mallory bodies     0.005
  Pre 18   8   0
  Post 26   0   0
Glycogen nuclei     0.001
  Pre   8   7 11
  Post 13   8   5
Lobular inflammation < 0.001
  Pre   1 23   2 0
  Post 15 11   0 0
Portal inflammation   0.05
  Pre   1 23   2 0
  Post   7 19   0 0
Fibrosis     0.001
  Pre   1 17   6 2 0
  Post   9 12   4 1 0
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BMI: Body mass index; HDL-C: High density lipoprotein cholesterol; 
LDL-C: Low density lipoprotein cholesterol; AST: Aspartate aminotrans-
ferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transfer-
ase; HOMA: Homeostatic model assessment method.
surgery and biopsy in patients with or without significant 
fibrosis [432 ± 133 d vs 530 ± 122 d respectively, P = not 
significant (NS)]. Equally, there was no difference in the 
average rate of  weight loss in patients with or without 
significant fibrosis (0.81 ± 0.26 kg/wk vs 0.66 ± 0.21 kg/
wk respectively, P = NS). 
DISCUSSION
In this study, we have demonstrated that, in patients with 
morbid obesity, weight loss induced by a mixed bariatric 
surgery (combination of  malabsorptive and restrictive, 
Roux-en-Y gastric bypass with a modified Fobi-Capella 
technique) dramatically improved nonalcoholic fatty liver 
disease lesions observed in these patients. 
There are various types of  bariatric procedures. Ini-
tially, the most commonly used were primarily malabsorp-
tive. Using these techniques, most of  the obesity-related 
liver abnormalities did not improve, or even worsened. 
Jejunoileal bypass performed in the 1950-1970s was aban-
doned due to various complications, including significant 
hepatic lesions and even cirrhosis[24-26]. Numerous mecha-
nisms, such as malabsorption of  essential micronutrients, 
bacterial overgrowth and rapid weight loss with resulting 
massive influx of  free fatty acids, have been implicated in 
the pathogenesis of  NAFLD associated with jejunoileal 
bypass[27]. For example, Requarth et al[28] reported the long 
term morbidity after jejunoileal bypass in 453 patients and 
24 of  these developed acute liver failure (7%) and the 15 
years probability of  established cirrhosis was 8.1%.
More recently, restrictive or mixed techniques of  bariat-
ric surgery have been used. Lately, most of  the published 
studies have focused on the effect of  restrictive techniques 
on NAFLD. Thus, Dixon et al[10] used a laparoscopic ad-
justable banding technique that achieved a weight loss of  
around 50% and observed important improvements in 
steatosis, necroinflammatory changes and fibrosis. 
The bariatric surgery technique used by us is mixed, 
restrictive and mildly malabsorptive. The techniques 
which, like ours, use a gastric bypass, produce a greater 
weight loss than gastric banding and also are longer last-
ing[29,30]. It would be interesting to know if  these different 
types of  surgical approaches are accompanied by similar 
effects on the treatment of  liver lesions seen in obesity. 
Using a bariatric surgery technique that combines 
restriction with mild malabsorption, we obtained a signifi-
cant weight loss in patients. In addition, we have not only 
achieved a drastic remission of  steatosis, but also improve-
ments in lobular inflammatory activity and fibrosis. In 
our study, the percentage of  excess weight loss (72%) was 
clearly superior to that observed in the Dixon study (52%), 
previously cited[10]. Although other studies have been done 
with techniques other than merely restrictive, good results 
have also been found in improvement of  NAFLD[12,31].
It has been suggested that weight loss induced by 
malabsorptive procedures could disguise NASH improve-
ments after bariatric surgery because, in some patients, 
impairment in liver fibrosis could be observed. This ef-
fect was observed in the study performed by Kral et al[32] 
that used biliopancreatic diversion. They found a con-
stant improvement in metabolic syndrome but the effect 
on liver fibrosis varied. In their study, there was a frank 
improvement of  fibrosis in patients with pre surgery 
advanced fibrosis (grades 1-2) and, in contrast, “de novo” 
fibrosis appeared in patients that did not  have presurgery 
fibrosis. We have not observed this effect and the small 
number of  samples in which we observed persistence of  
fibrosis was in those patients with a presurgery fibrosis 
greater than stage 1. The difference in the results can be 
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Figure 2  Persistence of liver fibrosis after bariatric surgery (picrosirius stain, ×10). A: At surgery; B: Post-surgery. 
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Figure 3  Evolution of fibrosis score in the liver biopsies of 26 patients 
with bariatric surgery. 
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explained because Kral et al[32] found alcohol ingestion as 
a predictive factor of  increasing fibrosis. Our series did 
not include alcoholic patients and this argues in favor of  
the fact that the increasing fibrosis seen in the Kral study 
was not related to the type of  intervention, but to alco-
holic ingestion post surgery. 
In our study we saw a global improvement in portal 
fibrosis. Nevertheless, there were patients whose fibrosis 
did not improve; in 15 patients it remained stable. Barker 
et al[14] performed liver biopsy at surgery and postop-
eratively in 19 patients, mostly women without alcohol 
ingestion with a bariatric surgery technique similar to 
that used in our study, and found a frank improvement 
in fibrosis lesions, except in 4 patients whose lesions re-
mained stable. Probably this slightly greater improvement 
in fibrosis can be explained by a longer interval between 
surgery and performance of  the second biopsy. It was 21 
mo in Barker’s study and 16 mo in our work. 
Similarly to Barker et al[14] and other studies about 
liver improvement of  NASH with treatment[10,33], we also 
evidenced a persistence of  portal inflammation. In most 
of  our patients it was mild at surgery and significantly 
improved when it was analyzed globally; but in 19 pa-
tients some degree of  portal inflammation persisted. This 
phenomenon is frequent and it has been suggested that 
these portal changes do not have a direct relationship 
with metabolic syndrome or insulin resistance[10,33]. 
When the factors that could predict persistence of  
significant liver fibrosis were analyzed, biochemical and 
clinical factors at the time of  biopsies had low statistical 
power. The most important predictive factors were histo-
logical. Liver fibrosis and steatosis score at surgery were 
statistically associated with the persistence of  significant 
fibrosis in liver biopsy post surgery. It has been demon-
strated that steatosis at surgery and insulin resistance in-
fluence persistence of  steatosis after bariatric surgery[34], 
but the influence of  steatosis on the persistence of  fibro-
sis has not been clearly demonstrated. In our work, we 
found that, not only liver fibrosis at surgery, but also ste-
atosis score has an influence on the persistence of  fibro-
sis. It is known that a fatty liver is more vulnerable to fac-
tors that lead to fibrosis[35] and in the presence of  chronic 
liver diseases, steatosis may exacerbate liver injury[36]. The 
persistence of  liver fibrosis in our patients mediated by 
various factors may be helped by the previous existence 
of  a severe degree of  steatosis. 
Finally, patients with a persistence of  significant fi-
brosis had a lower level of  aminotransferases than those 
patients whose fibrosis was maintained or improved. 
This finding probably has low relevance, because in 
both groups aminotransferase levels were within normal 
range and it is also known that ALT values progressively 
decrease after BMI > 30 kg/m2; therefore, it frequently 
happens that patients with morbid obesity have normal 
values of  aminotransferase[27].
In conclusion, we have demonstrated that bariatric 
surgery, using a restrictive and mildly malabsorptive 
procedure, has a strong effect on improvement of  liver 
abnormalities associated with non alcoholic fatty liver 
disease in the morbidly obese, although any significant 
changes were observed in aminotransferase enzymes.
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score after surgery. And it is a very interested study that discusses the benefits 
of surgically induced effects on obese patients with NAFLD. 
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